Castle Biosciences (CSTL) Capital Leases (2023 - 2026)

Castle Biosciences has disclosed Capital Leases across 4 years of filings, most recently posting $288000.0 for Q1 2026.

• Capital Leases for Q1 2026 came in at $288000.0, down 12.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $288000.0 (down 12.2% YoY), and the FY2025 annual result was $314000.0, up 0.96% from the prior year.
• Capital Leases came in at $288000.0 for Q1 2026 at Castle Biosciences, down from $314000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $364000.0 in Q2 2025 to a low of $25000.0 in Q4 2023.
• The 4-year median for Capital Leases is $312000.0 (2024), against an average of $285555.6.
• Across the five-year window, Capital Leases soared 1144.0% in 2024 and declined 12.2% in 2026, its largest moves.
• Castle Biosciences' Capital Leases stood at $25000.0 in 2023, then jumped by 1144.0% to $311000.0 in 2024, then grew by 0.96% to $314000.0 in 2025, then fell by 8.28% to $288000.0 in 2026.
• The last three Capital Leases figures came in at $288000.0 (Q1 2026), $314000.0 (Q4 2025), and $339000.0 (Q3 2025), per Business Quant data.